What Maltofer Fol Treats: Main Uses and Benefits

Maltofer Fol is primarily applied for the supportive management of symptoms related to systemic imbalance caused by iron and folic acid deficiency. The medication is used to address these deficiency states and their associated symptomatic burden.

The therapeutic benefit focuses on easing fatigue, weakness, and low energy associated with iron deficiency anemia. It is also relevant for managing combined deficiencies of both iron and folic acid, and for nutritional support during high-need states like pregnancy and lactation.

“The formulation supports patients in coping more steadily with the difficult symptoms of iron deficiency by being well-tolerated.”

It generally helps address symptom clusters that interfere with daily comfort, such as persistent weakness and fatigue. The dual-component formulation supports the body's processes for red blood cell formation, which is relevant for supporting healthy fetal development during pregnancy. Furthermore, the specific Iron(III)-hydroxide polymaltose complex may assist with managing symptoms related to physical discomfort often caused by traditional iron supplements, like constipation or nausea, contributing to improved comfort and supports the patient in adhering to the management plan.

Quick Fact: Relief for persistent fatigue and weakness associated with low iron.

Regulatory References

1. FDA Verification Portal

Who can and cannot use Maltofer Fol?

This section outlines the eligibility and non-eligibility for Maltofer Fol based on official regulatory information. Eligibility is strictly defined by conditions and population groups stated in government labeling.

Contraindications (Must not use)

Individuals must not use Maltofer Fol if they have:

• Known hypersensitivity or allergy to iron polymaltose, folic acid, or any other ingredient.
• Iron overload conditions (such as haemochromatosis or haemosiderosis).
• Anaemia not caused by iron deficiency (e.g., megaloblastic anaemia due to Vitamin B12 deficiency).
• Disturbances in iron utilisation (e.g., lead anaemia, sidero-achrestic anaemia, thalassaemia).

Special Considerations and Restrictions

Use is generally established for adults and adolescents (12 years and older) who require iron and folic acid supplementation, provided none of the contraindications are present.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Maltofer Fol based on the distinct behaviors of its two active ingredients: Iron(III)-Hydroxide Polymaltose Complex and Folic Acid.

Iron Component (Complex Iron)

Due to the non-ionic, complex-bound structure of the iron component, official labels state that the classic ionic interactions seen with traditional ferrous salts are unlikely to occur. This includes co-administration with substances like Tetracyclines, Antacids, and food components (e.g., oxalates or phytin). However, the co-administration of Parenteral Iron Preparations (injectable iron) is not recommended, as this combination has been shown to inhibit the absorption of the oral iron complex.

Folic Acid Component

The Folic Acid component is associated with several documented drug-drug interactions, primarily involving exposure modification and antagonism:

• Anticonvulsants: Folic acid may increase the metabolism of certain anti-seizure medicines, including Phenytoin, Phenobarbital, and Primidone, resulting in lower serum concentrations of these drugs.
• Folic Acid Antagonists: The effects of agents such as Methotrexate and Pyrimethamine may be mutually inhibited when co-administered.
• Absorption Modifiers: The absorption of the folic acid component may be reduced by certain medications like Sulfasalazine or substances such as Ethanol and Green Tea.
• Mineral Supplement: Folic acid may also reduce the intestinal absorption of Zinc from co-administered supplements.

Maltofer Fol's active component is Iron (III)-Hydroxide Polymaltose Complex (IPC). This non-ionic complex facilitates the uptake of iron. The IPC structure allows for a controlled uptake mechanism: iron is absorbed in the small intestine via an active absorption process known as competitive ligand exchange, mediated by specific proteins on the brush border, such as the integrin receptor. Once inside the enterocyte, the iron is bound to ferritin, which functions as the primary intracellular iron storage protein. It is then released into the plasma and oxidized to Fe^3+ before binding to transferrin for transport to the bone marrow for erythropoiesis. The non-ionic state is proposed to limit interaction with the mucosal lining and avoid overwhelming the divalent metal transporter 1 (DMT1) pathway. The folic acid component provides the necessary C1 units essential for the synthesis of purines and pyrimidines, which are prerequisites for DNA replication and subsequent red blood cell maturation, thereby influencing the rate of erythrocyte production. The sequential transport and utilization of iron contribute to the processes that increase hemoglobin and serum ferritin levels.

How to Use Maltofer Fol

The parameters for using Maltofer Fol focus on the proper route, dosage, timing, and duration of therapy. The medicine is intended for oral use and is supplied as chewable tablets containing 100 mg of elemental iron (as Iron(III)-Hydroxide Polymaltose Complex) and 0.35 mg of Folic Acid.

Administration Scope

The dosage frequency allows the total daily amount to be taken once daily or to be divided into separate doses. For specific populations, such as pregnant women, the regimen typically involves starting with the higher treatment dose (2–3 tablets daily) until laboratory values normalize, followed by the maintenance dose (1 tablet daily) for continued use until the end of the pregnancy to replenish iron reserves.

Usage typically involves two phases: an initial treatment phase that continues until the hemoglobin value is normalized, followed by a continuation phase lasting several weeks to months to adequately replenish the body's iron stores (Ferritin). This structured approach facilitates the replenishment of iron levels through a standardized protocol.

Research Evidence / Overview of studies for Maltofer Fol

The research base for Maltofer Fol centers on clinical trials and scientific reviews examining the components, specifically the Iron(III)-Hydroxide Polymaltose Complex (IPC) and Folic Acid, across defined time intervals. These studies contribute to the broader evidence landscape by monitoring specific physiological changes and patient-reported outcomes.

Evidence for Use in Addressing Iron Deficiency Anemia

Studies conducted for the active ingredients have primarily included Randomized Controlled Trials (RCTs) and Systematic Reviews that research explored in the context of Iron Deficiency Anemia (IDA). Research examined adult patients with confirmed IDA and adolescents, often involving comparator research where the IPC iron formulation was observed alongside traditional ferrous iron salts. Outcomes monitored included changes in blood markers like hemoglobin levels and iron storage biomarkers such as serum ferritin.

Findings describe patterns observed in the studies related to biomarker changes recorded during the study period. Studies report how symptoms evolved in the observed populations, particularly for outcomes related to systemic or functional imbalance associated with low iron levels. Treatment adherence was associated with patient-reported comfort levels.

Comparative Studies on Patient Experience and Tolerability

Research explored short-term symptom changes by comparing the IPC to other common oral iron forms. These comparative studies focused on applying in research contexts involving patient-reported experiences, specifically tracking the incidence and intensity of outcomes related to physical discomfort (e.g., nausea, constipation).

Research describes that certain gastrointestinal discomforts were reported differently when the IPC formulation was used, compared to simple ferrous salts, in some studies. Data show patterns related to treatment adherence and compliance rates when comparing the different iron formulations. Findings help contextualize how patients reported their experience.

Evidence for Nutritional Support During Pregnancy

Research has included controlled trials and systematic reviews that specifically evaluated iron-folic acid supplementation protocols for pregnant women. Studies monitored maternal hemoglobin and folate levels over the trimesters to determine change. Evidence derived from settings with varying symptom burdens describes patterns of adherence to the management plan, and these patterns were associated with patient-reported tolerability.

Research Gaps and What Remains Uncertain

The duration of research studies is an important factor in understanding the available evidence. Long-term effects are not well-characterized, and there is limited information for outcomes related to sustained maintenance. A key limitation is that comparative evidence is lacking for the specific dual formulation against other iron-folic acid combination supplements currently on the market. Additionally, subgroup findings are uncertain for specific co-morbidity-defined groups. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Philippines FDA Verification Portal: Patient Information Leaflet (PIL) for Iron(III)-Hydroxide Polymaltose Complex and Folic Acid
2. WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification B03AD04 (Iron in combination with folic acid)

Common questions about Maltofer Fol (FAQ)

Q: Does Maltofer Fol have a warning about accidental overdose for children?

A: Yes. Regulatory information includes a specific warning about the risk of accidental iron overdose, which is a leading cause of fatal poisoning in children under six years old. Regulatory documents emphasize the importance of keeping the product strictly out of the sight and reach of children.

Q: Is Maltofer Fol suitable for people with kidney concerns?

A: Regulatory documents state that clinical experience regarding the use of this medicine in patients with kidney impairment is very limited. Consultation with a medical practitioner is necessary if there are pre-existing kidney concerns, as clinical data for this population are limited.

Q: How does Maltofer Fol differ from the standard Maltofer product?

A: The difference lies in the composition. Maltofer Fol is a combination preparation containing both the Iron(III)-Hydroxide Polymaltose Complex and Folic Acid. The standard Maltofer product, by contrast, typically contains only the iron complex.

Q: Are there different forms (tablets, drops, syrup) of Maltofer Fol available?

A: The Maltofer family of products, which share the same iron compound, is often available in various forms, such as chewable tablets, oral drops, and oral syrup. The specific forms and product variations available may differ depending on your country.

Q: Can Maltofer Fol be taken at the same time as my thyroid medication?

A: Official product information notes that iron-containing supplements are generally known to interfere with the absorption of thyroid hormones, such as levothyroxine. This potential interaction carries the risk of altering the absorption of thyroid medication. Regulatory guidance often recommends separating the doses of iron and thyroid medication by several hours.

Q: Is there research on Maltofer Fol for treating conditions other than iron deficiency?

A: Official documents state that this medicine is indicated for the treatment and prevention of iron deficiency and iron deficiency anemia. The medicine is formally indicated only for the treatment and prevention of iron deficiency and iron deficiency anemia, according to regulatory labels.

Q: How quickly should I expect to feel a change after starting Maltofer Fol?

A: Official guidance focuses on clinical markers of change rather than subjective feelings. A rise in hemoglobin levels is typically monitored every four weeks, which indicates the treatment is working. The overall duration often involves a continuation phase of several weeks to months to ensure iron stores are fully replenished.

Q: Does Maltofer Fol interact with coffee or tea?

A: Studies and official information indicate that the absorption of the Iron(III)-Hydroxide Polymaltose Complex in this medicine is not reduced by the consumption of common beverages like coffee or tea. This difference is often noted when compared to traditional ferrous iron supplements.

Q: Is there a maximum amount of time I can take Maltofer Fol?

A: The recommended course of therapy is typically divided into two phases: an initial treatment phase and a continuation phase to replenish iron stores. The continuation phase often lasts for approximately three months after hemoglobin levels have normalized. Any decision regarding long-term use extending beyond the standard period requires professional management.

Q: Is Maltofer Fol absorbed better than other types of iron?

A: Regulatory information describes that the Iron(III)-Hydroxide Polymaltose Complex (IPC) uses a non-ionic, controlled uptake mechanism, which is different from traditional ferrous salts. While studies report comparable overall iron utilization between the two forms, this distinct mechanism is associated with differences in reported gastrointestinal tolerability.

Q: Can I take other vitamins while using Maltofer Fol?

A: Regulatory documents advise caution when co-administering this medicine with other mineral supplements. Specifically, the Folic Acid component may reduce the intestinal absorption of Zinc. Interactions with specific vitamins or minerals should be reviewed by a healthcare provider.

Q: Does the time of day matter when taking Maltofer Fol?

A: The official administration schedule requires the tablet to be taken during or immediately after a meal. While the total daily amount can be taken once a day, clinical research suggests that morning dosing may be favored. This is based on the body's natural circadian rhythm for regulating iron absorption.

Q: Can I crush the tablet or open the capsule of Maltofer Fol?

A: The preparation requirements for the chewable tablet state that it can be chewed or swallowed whole. Guidance on crushing the tablet for specialized administration, if a patient experiences difficulty swallowing, can be found by reviewing the official prescribing information or by consulting a pharmacist.

Q: Is the folic acid component in Maltofer Fol enough for my needs?

A: Maltofer Fol is formulated to provide 0.35 mg of Folic Acid, which is intended to support red blood cell formation and address concurrent folate deficits. The determination of the appropriate total folate requirement must be reviewed by a medical practitioner.

Q: Can I continue my regular diet while taking Maltofer Fol?

A: Yes. Studies indicate that the Iron(III)-Hydroxide Polymaltose Complex has minimal interaction with most common food components, unlike some traditional iron salts. Therefore, the absorption of the iron is generally not impaired when taken with meals or common beverages like coffee and dairy.

Storage and Disposal Instructions

The storage and disposal of Maltofer Fol must strictly follow the official instructions provided on the regulatory label to maintain product integrity and ensure safety.

Storage Requirements

• Temperature and Environment: The medicine must be stored in a cool, dry place, generally kept below 25 C or 30 C as specified by the national label. It must be protected from heat, light, and moisture, which means avoiding storage in wet areas, like bathrooms, or in direct sunlight.
• Packaging: Keep the tablets in their original packaging or outer carton to provide necessary protection from light until the labeled expiry date.
• Child Safety: A mandatory requirement is to keep all tablets out of the sight and reach of children.

Disposal

To prevent environmental contamination and misuse, Maltofer Fol should not be disposed of in household trash or poured into wastewater. Unwanted or expired medicine must be returned to a pharmacist or official collection point for safe pharmaceutical waste management.